Abstract
On 17 January 2007, the European Group of Ethics (EGE) issued a draft report that recognized the potential of nanomedicine in terms of developing new diagnostics and therapies (http://ec.europa.eu/european _group_ethics/activities /ethics_en.htm). The group proposes that measures be established to verify the safety of nanomedical products and devices, and calls on the relevant authorities to carry out a proper assessment of the risks and safety of nanomedicine. This chapter deals with toxicological aspects of various nanoparticles such as polymer-drug conjugates, carbon nanotubes, quantum dots, dendrimers and other various nanostructures. The nanoparticle-biological organism interactions and immunological risk of the nanoparticles are also examined in this chapter.
Keywords: Polymeric nanoparticles, nanomedicines, hydroxyapatite, carbon nanotubes, phagocytosis, quantum dots, polymeric nanomedicines, biocompatibility, HPMA, drug delivery systems, pluronic, chitosan, nanomaterials, polymer-drug conjugates, doxorubicin.
Related Books
Frontiers in Nano and Micro-Device Design for Applied Nanophotonics, Biophotonics and Nanomedicine
Frontiers in Nanomedicine
Frontiers in Nanomedicine
Nanomaterials and Their Interactive Behavior with Biomolecules, Cells and Tissues
Nanotherapeutic Strategies and New Pharmaceuticals (Part 1)
Nanotherapeutic Strategies and New Pharmaceuticals (Part 2)
On-Chip Pretreatment of Whole Blood by Using MEMS Technology
Toxic Effects of Nanomaterials
Frontiers in Biomaterials
Frontiers in Biomaterials